At 8.2% CAGR, Europe Bioreactors Market is Projected to be Worth US$ 1,732.95 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Europe bioreactors market was valued at US$ 919.86 million in 2022 and is expected to reach US$ 1,732.95 million by 2030, registering a CAGR of 8.2% from 2022 to 2030. Technological advancements in bioreactors and rising demand for personalized medicine are among the critical factors attributed to the Europe bioreactors market expansion.             

Advancement in the field of bioreactors has opened many opportunities for the market players. Leading players have come up with innovative products in the last few years. The improvement in the bioreactors offers a faster and easier production of biopharmaceuticals at reduced production costs. Also, the investments from public and private investors are rising for the bioreactors. The rise in the venture is enabling technological developments and standard biological parts. In February 2021, WuXi Biologics' MFG5 Drug Substance (DS) manufacturing facility in China launched a GMP operation with a capacity of 36,000L and deployed nine 4,000L single-use bioreactors. As a major milestone in the company's global capacity planning, the GMP implementation of MFG5 increases WuXi Biologics' current capacity to 90,000L, significantly expanding its ability to support global partners.

The new bioreactors are developed for the growth of adherent cells on microcarriers that enable rapid, scalable cell culture processes in the development of vaccines. The launch of such new bioreactors enhanced the portfolio of the company in the bioreactors market. In June 2022, ABEC announced that mAbxience plans to add a 4,000L single-use custom single-run (CSR) bioreactor to its state-of-the-art cGMP facility in León, Spain. In May 2021, Beckman Coulter Life Sciences launched its next-generation Biolector XT microbioreactor in Germany. The BioLector XT microbioreactor enables monitoring of cultivation parameters, high-throughput strain screening, and optimization of feeding strategy.

Advancement in bioreactors has added various solutions for most industries, such as pharmaceutical, petrochemical, food, and agriculture. Therefore, technological advancements are expected to boost innovations in the bioreactors market in the coming years.

On the contrary, stringent regulatory framework hurdles the growth of Europe bioreactors market. 

Based on scale, the Europe bioreactors market is categorized into lab-scale production, pilot-scale production, and full-scale production. The pilot-scale production segment held 48.4% share of Europe bioreactors market in 2022, amassing US$ 444.87 million. It is projected to garner US$ 825.98 million by 2030 to expand at 8.0% CAGR during 2022–2030.

In terms of application, the Europe bioreactors market is segmented into microbial application, cell culture application, and others. The cell culture application segment held 48.6% share of Europe bioreactors market in 2022, amassing US$ 446.72 million. It is projected to garner US$ 830.04 million by 2030 to expand at 8.1% CAGR during 2022–2030.

By technology, the Europe bioreactors market is bifurcated into fed-batch bioreactors and perfusion bioreactors. The fed-batch bioreactors segment held 62.1% share of Europe bioreactors market in 2022, amassing US$ 570.80 million. It is projected to garner US$ 1,032.35 million by 2030 to expand at 7.7% CAGR during 2022–2030.

Based on end user, the Europe bioreactors market is segmented into biopharma manufacturers, research and development organizations, and contract manufacturing organization. The research and development organizations segment held 60.4% share of Europe bioreactors market in 2022, amassing US$ 555.84 million. It is projected to garner US$ 1,102.99 million by 2030 to expand at 8.9% CAGR during 2022–2030.

Based on country, the Europe bioreactors market has been categorized into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.5% share of Europe bioreactors market in 2022. It was assessed at US$ 271.45 million in 2022 and is likely to hit US$ 610.86 million by 2030, exhibiting a CAGR of 10.7% during 2022–2030.            

Key players operating in the Europe bioreactors market are Applikon Biotechnology BV, bbi-biotech GmbH, Cellexus International Ltd, General Electric Co, Merck KGaA, Pall Corp, PBS Biotech Inc, Sartorius AG, Solaris Biotechnology SRL, and Thermo Fisher Scientific Inc, among others.

• In March 2022, Cellexus partnered with Castleford-based Verder Liquids to provide pumps to be used for the acid / base pump, included as standard with the CellMaker Plus and Low Flow bioreactor systems. This pump allows the CellMaker to inject acids or alkali from their reservoir directly into the bioreactor bag by manual or automated operation.
• In October 2023, Thermo Fisher Scientific Inc expanded its manufacturing capacity in St. Louis. The expansion will support biologic therapies for diseases such as cancer, auto-immune conditions, and rare genetic disorders. The manufacturing facility center has installed four Thermo Scientific DynaDrive Single-Use Bioreactors, and each of the bioreactors can process up to 5,000 liters of biologics.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com